C4 Therapeutics Inc (CCCC) Stock: Navigating the Market Volatility

In the past week, CCCC stock has gone down by -0.50%, with a monthly decline of -26.03% and a quarterly surge of 21.17%. The volatility ratio for the week is 5.19%, and the volatility levels for the last 30 days are 7.49% for C4 Therapeutics Inc The simple moving average for the last 20 days is -14.34% for CCCC’s stock, with a simple moving average of 84.37% for the last 200 days.

Is It Worth Investing in C4 Therapeutics Inc (NASDAQ: CCCC) Right Now?

The stock has a 36-month beta value of 3.19. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

The public float for CCCC is 57.73M, and at present, short sellers hold a 9.16% of that float. On April 04, 2024, the average trading volume of CCCC was 4.09M shares.

CCCC) stock’s latest price update

C4 Therapeutics Inc (NASDAQ: CCCC)’s stock price has soared by 2.86 in relation to previous closing price of 7.68. Nevertheless, the company has seen a loss of -0.50% in its stock price over the last five trading days. GlobeNewsWire reported 2024-03-05 that CFT1946 Data Demonstrates Promising Single Agent and Combination Activity in Preclinical Models of BRAF V600X Melanoma, Colorectal Cancer, Non-Small Cell Lung Cancer and Brain Metastasis CFT1946 Data Demonstrates Promising Single Agent and Combination Activity in Preclinical Models of BRAF V600X Melanoma, Colorectal Cancer, Non-Small Cell Lung Cancer and Brain Metastasis

Analysts’ Opinion of CCCC

Many brokerage firms have already submitted their reports for CCCC stocks, with JP Morgan repeating the rating for CCCC by listing it as a “Neutral.” The predicted price for CCCC in the upcoming period, according to JP Morgan is $6 based on the research report published on January 29, 2024 of the current year 2024.

Stifel, on the other hand, stated in their research note that they expect to see CCCC reach a price target of $12, previously predicting the price at $2. The rating they have provided for CCCC stocks is “Buy” according to the report published on December 13th, 2023.

Credit Suisse gave a rating of “Neutral” to CCCC, setting the target price at $10 in the report published on February 24th of the previous year.

CCCC Trading at -1.82% from the 50-Day Moving Average

After a stumble in the market that brought CCCC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -33.50% of loss for the given period.

Volatility was left at 7.49%, however, over the last 30 days, the volatility rate increased by 5.19%, as shares sank -24.76% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +38.60% upper at present.

During the last 5 trading sessions, CCCC fell by -0.50%, which changed the moving average for the period of 200-days by +118.84% in comparison to the 20-day moving average, which settled at $9.09. In addition, C4 Therapeutics Inc saw 39.82% in overturn over a single year, with a tendency to cut further gains.

Stock Fundamentals for CCCC

Current profitability levels for the company are sitting at:

  • -6.7 for the present operating margin
  • 0.63 for the gross margin

The net margin for C4 Therapeutics Inc stands at -6.34. The total capital return value is set at -0.42. Equity return is now at value -49.50, with -32.82 for asset returns.

Based on C4 Therapeutics Inc (CCCC), the company’s capital structure generated 0.22 points at debt to capital in total, while cash flow to debt ratio is standing at -1.51. The debt to equity ratio resting at 0.29. The interest coverage ratio of the stock is -133.81.

Currently, EBITDA for the company is -131.29 million with net debt to EBITDA at 0.42. When we switch over and look at the enterprise to sales, we see a ratio of 23.43. The receivables turnover for the company is 1.76for trailing twelve months and the total asset turnover is 0.06. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.34.

Conclusion

To sum up, C4 Therapeutics Inc (CCCC) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Related Posts